Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L),, a developer of rapid health information technologies, announces that sales in the second quarter ended June 30, 2017 were among the strongest since the Company's admission to NASDAQ Capital Market in 2014.

The Company recorded revenues of approximately $1.2 million over the three-month period, representing an increase of approximately 25 percent over the second quarter of 2016, and a 1.8 times increase over the first quarter of 2017. Revenues were derived from product sales in all key geographic regions (U.S., China and Rest of World) and were comprised of sales across Akers Bio's core commercialized product lines including components associated with the Company's PIFA Heparin/PF4 Rapid Assay products for sale internationally, and MPC breathalyzer based products.

Akers Bio intends to file its Form 10-Q containing the financial statements for the three months and six months ended June 30, 2017 after U.S. market close on Monday, August 14, 2017.

About Akers Biosciences, Inc.

Akers Bio develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

Additional information on the Company and its products can be found at www.akersbio.com. Follow us on Twitter @AkersBio.